Related by context. All words. (Click for frequent words.) 73 preclinical 72 GLP toxicology studies 71 IND submission 70 Phase 2a clinical trials 69 Phase IIb clinical trials 68 preclinical toxicology 68 Phase IIa trials 68 Phase Ib 67 PDE4 inhibitor 67 Fx #A 67 Phase #b/#a 66 Phase 2b clinical trials 66 CB2 selective receptor agonist 66 PLK1 SNALP 66 Phase IIb trials 65 Phase Ib study 65 phase IIa 65 Phase 2a trial 65 Phase 2b study 65 Phase 2b clinical 65 XOMA 3AB 64 phase IIb 64 MEK inhibitor 64 Phase III clinical 64 preclinical studies 64 phase IIa clinical 64 confirmatory Phase III 64 midstage trials 64 Phase III clinical trials 64 Phase IIa clinical trials 64 glucokinase activator 64 phase IIb clinical 64 IND Investigational New 64 ALN PCS 64 oral prodrug 63 Phase Ib clinical 63 Phase IIb 63 tezampanel NGX# 63 Phase Ib clinical trials 63 Phase IIa trial 63 R#/MEM # 63 GLP toxicology 63 AQ4N 63 Panzem R NCD 63 pivotal bioequivalence 63 romidepsin novel 63 tiapamil 63 BLA filing 63 PSN# [002] 63 TBC# 63 KNS # 63 JAK inhibitor 63 non nucleoside inhibitor 63 Phase IIb clinical 63 selective androgen receptor modulator 63 HCV protease inhibitor 63 TKB# 63 Factor VIIa 63 Phase Ia 63 Stimuvax R 63 Archexin 63 ANAVEX #-# [003] 62 Phase IIa 62 Protexia ® 62 AEG# 62 Cloretazine ® 62 confirmatory Phase 3 62 TKM ApoB 62 Aerosurf 62 targeted radiotherapeutic 62 histone deacetylase HDAC inhibitor 62 Neo Kidney Augment 62 INCB# [001] 62 SinuNase ™ 62 PANVAC VF 62 IIa trial 62 SAR# [004] 62 NDA submission 62 preclinical efficacy 62 OvaRex R 62 registrational 62 Phase lll 62 Phase 1b 62 Phase #b/#a trial 62 ATL# [001] 62 Phase 1a clinical 62 GLPG# 62 phase Ib 62 HGS# 62 molecular imaging radiopharmaceutical 62 Aurora kinase inhibitor 62 bardoxolone 62 BCX# 62 cannabinor 62 pradefovir 62 IMC #B 61 trastuzumab DM1 T DM1 61 Phase #/#a 61 ASONEP 61 Bicifadine 61 Phase 2a 61 cGMP manufacture 61 Phase 1b trial 61 Panzem R 61 Phase IIb trial 61 rPA anthrax vaccine 61 HCD# [002] 61 RhuDex ® 61 Cannabinor 61 Cintredekin Besudotox 61 OncoVEX GM CSF 61 ONCONASE R 61 HepeX B 61 HCV polymerase inhibitor 61 XL# anticancer compounds 61 investigational humanized monoclonal antibody 61 PREOS R 61 CCR9 antagonist 61 ganetespib 61 pivotal Phase III 61 Phase #b/#a clinical 61 Pimavanserin 61 IAP inhibitor 61 TRO# 61 CEQ# 61 registrational trial 61 APEX PD 61 TACI Ig 61 Phase IIB 61 clinical trials 61 ICA # 61 Phase III trials 61 EVIZON TM squalamine lactate 61 hypoxia activated prodrug 61 multiple ascending dose 61 Pharmos pipeline 61 Phase Ib II 61 Phase 1a 61 antibody MAb 61 Phase 1b clinical 61 XmAb ® 61 TOCOSOL Paclitaxel 61 IIa clinical 61 JAK2 inhibitor 60 Prodarsan ® 60 therapeutic monoclonal antibody 60 Phase II 60 PEG SN# 60 Anthim 60 Phase 2b trial 60 defensin mimetic antibiotic 60 Alzhemed TM 60 mGluR5 negative 60 Guanilib 60 Fentanyl TAIFUN R 60 FOLOTYN ® 60 DB# [003] 60 phase Ib clinical 60 nitric oxide donating prostaglandin 60 celgosivir 60 CD# CEA 60 Surfaxin LS 60 TELINTRA R 60 Phase 2b 60 HspE7 60 NGX# 60 vivo preclinical 60 LB# [003] 60 PNP inhibitor 60 tolevamer 60 anti CD3 monoclonal 60 PrevOnco 60 investigational hepatitis B 60 oral proteasome inhibitor 60 CRMD# 60 deforolimus 60 PXD# 60 novel histone deacetylase 60 Intarcia 60 oral methylnaltrexone 60 PF # [002] 60 SinuNase TM 60 Prednisporin TM 60 sterile lidocaine patch 60 subcutaneous formulation 60 CR# vcMMAE 60 HCV nucleotide polymerase inhibitor 60 PRT# 60 GALNS 60 triphendiol 60 SAR# [002] 60 nonclinical studies 60 huC# DM4 60 TELINTRA 60 Onconase 60 SUCCEED trial 60 Annamycin 60 candidate CRLX# 60 IMA# 60 initiate Phase 2b 60 torezolid phosphate 60 Prodarsan R 60 DXL# 60 forodesine 60 leading oral taxane 60 Spiegelmer ® 60 reslizumab 60 talactoferrin 60 recombinant biopharmaceutical 60 Angiocept 60 GSK# [002] 60 Allovectin 7 60 RGB # 60 seliciclib CYC# 60 Phase 2a clinical 60 PNT# 60 Hematide TM 60 phase IIb study 59 Phase III 59 Hematide ™ 59 Personalized Immunotherapy 59 outlicensing 59 GED aPC 59 initiate Phase IIb 59 ALN TTR# 59 Zenvia ™ 59 Corlux 59 huN# DM1 59 Onalta 59 Investigational 59 dose escalation Phase 59 EndoTAG TM -1 59 dirucotide 59 HuCAL antibodies 59 nalbuphine ER 59 class mGluR5 inhibitor 59 acyclovir Lauriad R 59 TKM PLK1 59 elotuzumab 59 Gentamicin Surgical Implant 59 Neo Kidney Augment ™ 59 Sulonex 59 Luveniq 59 MAXY alpha 59 generation purine nucleoside 59 generation PNP inhibitor 59 Bioral Amphotericin B 59 ATryn ® 59 Troxatyl 59 tezampanel 59 vosaroxin 59 MOR# 59 Preclinical studies suggest 59 Synavive 59 compound PMX # 59 phase IIb trial 59 XL# XL# 59 SparVax TM 59 OMP #R# 59 Phase IIa proof 59 DPX Survivac 59 CORT # 59 PF # [001] 59 lomitapide 59 Shigamabs R 59 L DOS# 59 volociximab 59 epothilone 59 thorough QT 59 REVIVE Diabetes 59 obatoclax 59 alvespimycin 59 Charlesson 59 MBP# [001] 59 vivo toxicology 59 Cutanea 59 Iluvien ® 59 candidate AQ4N 59 HQK 59 initiate Phase 59 AVN# [001] 59 dacetuzumab SGN 59 therapeutic antibody 59 Phase III Clinical Trial 59 Androxal TM 59 mertansine 59 Proellex TM 59 PEG PAL 59 Valortim TM 59 Veronate 59 AAG geldanamycin analog 59 midstage clinical 59 GAP #B# 59 STEDESA 59 aldehyde dehydrogenase ALDH2 deficiency 59 MAXY VII 59 Panzem 59 CCR5 antagonist 59 TLK# 59 CCX# 59 ongoing Phase IIIb 59 multicenter Phase II 59 Exherin TM 59 Ceflatonin R 59 INT# [002] 59 BLA submission 59 non nucleoside HCV 59 Phase IIIb clinical 59 Onalta ™ 59 NS5A inhibitor 59 HIV integrase inhibitor 59 Shigamabs ® 59 albiglutide 59 otelixizumab 58 vascular disrupting agent 58 RenaZorb TM 58 siRNA therapeutic 58 NOX E# 58 Trofex 58 cathepsin K inhibitor 58 mitogen activated ERK kinase 58 therapeutic monoclonal antibodies 58 Cutanea Life Sciences 58 IND CTA 58 oral nucleoside analogue 58 Phase III confirmatory 58 virus HCV protease inhibitor 58 Fodosine 58 Chimigen TM 58 nucleoside tide 58 PDX pralatrexate 58 IND 58 JZP 58 HCV polymerase 58 generation URAT1 inhibitor 58 PSMA ADC 58 INS# [001] 58 ALN TTR 58 humanized monoclonal antibody 58 Phenoptin 58 isoform selective 58 Stedivaze 58 Pivotal Phase III 58 velafermin belinostat 58 Initiate Phase 58 INDs 58 Dacogen injection 58 MGCD# [001] 58 telomerase therapeutic 58 novel peptides 58 Phase IIa clinical 58 Menerba 58 NPC 1C 58 Phase 2b Clinical Trial 58 zileuton CR 58 initiate Phase Ib 58 budesonide foam 58 Amigal 58 BEMA Granisetron 58 Kamada AAT 58 NP2 Enkephalin 58 opioid bowel dysfunction 58 peginesatide 58 Phase III Pivotal 58 XL# XL# XL# XL# 58 PS# [001] 58 Crofelemer 58 orally bioavailable 58 HDAC Inhibitor 58 orally administered inhibitor 58 tubulin inhibitor 58 anticancer compound 58 AKT inhibitor 58 NDA resubmission 58 RELOVAIR ™ 58 including eniluracil ADH 58 Prodarsan 58 Urocidin 58 Anticalin 58 inhaled liposomal ciprofloxacin 58 dacetuzumab 58 Locteron 58 Urocortin 2 58 AeroLEF TM 58 PRTX 58 ILUVIEN ® 58 Azedra ™ 58 synthetic retinoid 58 Zybrestat 58 AP# [003] 58 VQD 58 HCV protease 58 allosteric modulator NAM 58 RNAi therapeutic 58 Vilazodone 58 EGS# 58 Phase Ib IIa 58 dextofisopam 58 mGluR2 positive 58 Nanobody ® 58 phase 2a 58 Ultrafast Insulin 58 Lymphoseek ® 58 PRLX # 58 rxRNA 58 CBLC# 58 AERx iDMS 58 ophthalmic indications 58 midstage studies 58 QuatRx 58 ALN RSV# 58 Zemiva TM 58 Aganocide 58 IL# PE#QQR 58 Plicera 58 bicifadine 58 Anavex #-# 58 Zenvia Phase III 58 AIMM trial 58 Cyclooxygenase Inhibiting Nitric Oxide 58 Biologic License Application BLA 58 ApoB SNALP 58 Dyloject TM 58 SNT MC# 58 Tesetaxel 58 Protexia R 58 Carfilzomib 58 MOZOBIL 58 Kosan dependence 58 crofelemer 58 orally dosed 58 dyskinesia PD LID 58 Zerenex 58 Initiates Clinical 58 HCV polymerase inhibitors 58 ocular formulation 57 topical anti infective 57 investigational protease inhibitor 57 initiated Phase Ib 57 VEGF Trap 57 PD LID 57 Sym# 57 M Enoxaparin 57 MAXY G# 57 Excellarate TM 57 preclinical pharmacology 57 TMC# [002] 57 ADX# 57 maturation inhibitor 57 GVAX ® 57 DOS# 57 HGS ETR1 57 PHX# 57 StaphVAX R 57 Omacetaxine 57 apricitabine ATC 57 delta opioid receptor 57 Triapine 57 MKC# MT 57 investigational HCV polymerase 57 PREOS 57 IDX# 57 Solazed 57 liposomal formulation 57 AzaSite Plus 57 Trizytek 57 initiate Phase IIa 57 Belinostat 57 L BLP# 57 Tolerx 57 renin inhibitor 57 PSN# [001] 57 drug GAP #B# 57 Omigard 57 HCV antiviral 57 ORE# 57 peripherally acting 57 LE SN# 57 HepeX B TM 57 Allovectin 7 r 57 OvaRex ® MAb 57 Civacir 57 lorvotuzumab mertansine 57 Curaxin 57 polymerase inhibitor 57 ALTROPANE R 57 fusion inhibitor 57 Dalbavancin 57 PrevOnco ™ 57 Kahalalide F 57 Fibrillex TM 57 Azedra TM 57 antisense drug 57 telomerase inhibitor drug 57 multicenter Phase 57 Japanese Encephalitis vaccine 57 Tarvacin TM 57 MEK inhibitor RDEA# 57 faropenem 57 mGluR5 NAM 57 OXi# 57 Mpex 57 vivo validation 57 ART# 57 Nasdaq PGNX today 57 candidate REP# 57 intranasal formulation 57 CRLX# 57 Novolimus 57 Parkinson disease levodopa induced 57 polymerase inhibitors 57 XmAb# 57 TRX1 57 tramiprosate Alzhemed TM 57 RiVax 57 opioid induced bowel dysfunction 57 ELND-#/AZD-# 57 IAP inhibitors 57 TRANSDUR Bupivacaine 57 preclinically 57 GRN# 57 Azixa 57 Juvaris 57 Octreotide 57 Chemophase 57 Acetavance TM intravenous acetaminophen 57 Allovectin 7 R 57 forodesine hydrochloride 57 PORxin TM 57 Balaglitazone 57 omacetaxine mepesuccinate 57 Aurexis 57 Diamyd ® 57 Aurora kinase inhibitors 57 epigenetic therapies 57 pafuramidine 57 ATL# [002] 57 CRD5 57 oral calcitonin 57 Celator 57 GGF2 57 MKC# MKC# PP 57 SPP# [002] 57 CDP# 57 siRNA therapeutics 57 Virulizin R 57 Excellarate 57 OncoVEX 57 MAA submission 57 Peptimmune 57 incyclinide 57 IMGN# 57 ZEVALIN ® 57 ongoing Phase 1b 57 IMPDH inhibitor 57 TKM Ebola 57 New Drug IND 57 balsalazide tablet 57 Daclizumab 57 ANG# 57 protein kinase inhibitor 57 CG# [003] 57 Proteo 57 BrachySil 57 overactive bladder AA# 57 Insegia 57 lintuzumab SGN 57 romazarit 57 oral treprostinil 57 kinase inhibitor 57 maribavir 57 compound INCB# 57 Aganocide ® 57 Hsp# Inhibitor 57 Elagolix 57 NEUMUNE 57 KRN# 57 vidofludimus 57 LUVENIQ 57 THR beta agonist 57 GPR# agonist 57 intravenous acetaminophen 57 Tragara 57 JAK2 Inhibitor 57 COSIRA trial 57 Files Investigational 57 NABTT 57 next generation URAT1 57 LEP ETU 57 Exherin 57 Nanobody 57 Vicinium TM 57 oral PTH 57 receptor tyrosine kinase inhibitor 57 IIa trials 57 Icatibant 57 voreloxin 57 confirmatory pivotal 57 T Pred 57 MT#/MEDI-# 57 Maribavir 57 Viprinex 57 AOP Orphan 57 ASONEP TM 57 Panzem NCD 57 liprotamase 57 initiate Phase 1b 57 NVA# 57 Poly ICR 57 aurora kinase 57 eniluracil 57 OMP #M# 57 blinded randomized placebo controlled 57 IGN# 57 RDEA# 56 Anturol TM 56 rNAPc2 56 Solazed TM 56 Cloretazine R 56 PMA submission 56 Phase III pivotal 56 WX UK1 56 JAK1 56 nicotinic alpha 7 56 severe hypercholesterolemia 56 PEGylated 56 Myocet 56 Mipomersen 56 SCIB1 56 Nuvion 56 Aryplase 56 Inotek Pharmaceuticals Corporation 56 muscarinic receptor agonist 56 factor VIIa 56 Ostabolin C TM 56 oritavancin 56 PRX # 56 SILENOR TM 56 personalized dendritic cell 56 HCV NS5B polymerase 56 LUMINATE 56 trodusquemine 56 ALN VSP 56 ibudilast 56 Valortim 56 MT# MEDI 56 ADME 56 clinical 56 AMPAKINE CX# 56 selectin antagonist 56 Delafloxacin 56 rALLy clinical trial 56 dexanabinol 56 CYT# vascular disrupting 56 Hedgehog antagonist 56 teduglutide 56 Cloretazine 56 GRNVAC1 56 PREGNANT Study 56 POSIDUR TM ELADUR TM 56 ZFP Therapeutic 56 5 HT6 antagonist 56 Romidepsin 56 pharmacodynamic PD 56 Trophos 56 European Sepsis Trial 56 Talotrexin 56 KSP inhibitor 56 midstage clinical trials 56 RSD# 56 Oglemilast 56 cilengitide 56 successfully commercialize Iluvien 56 Alferon N 56 EP #R 56 Relypsa 56 KRYSTEXXA TM pegloticase 56 Zemiva ™ 56 Prednisporin 56 MEND CABG II 56 ulimorelin 56 systemic RNAi therapeutic 56 DAVANAT R 56 lucinactant 56 DNA RNA Medicines 56 SMT C# 56 intravenous ghrelin agonist 56 PCK# 56 BEMA TM Fentanyl 56 Anidulafungin 56 HuMax EGFr 56 IV APAP 56 XP# XP# 56 NPSP# 56 urocortin 2 56 lead Aganocide compound 56 CCR5 mAb 56 Nasulin 56 BAY #-# 56 ospemifene 56 PGL# 56 oral ridaforolimus 56 Alfimeprase 56 Study #CL# 56 LibiGel Phase III 56 VitiGam 56 Memryte 56 QLT# 56 oxymorphone ER 56 LHRH antagonist 56 H#N# VLP vaccine 56 confirmatory clinical 56 PEG Interferon lambda 56 dose escalation trial 56 Phase IIb III 56 CytoFabTM 56 SCH # 56 Topical Interferon Alpha 2b 56 ALN HPN 56 inhaled formulation 56 Somatuline R Autogel R 56 Nasdaq HALO 56 LentiVector technology 56 BrachySil TM 56 novel anticancer 56 Cetrorelix 56 ISIS # 56 NTDDS 56 Anaphore 56 Iloperidone 56 Ophthotech 56 Cloretazine R VNP#M 56 ALN VSP Phase 56 Oncaspar 56 Zensana TM 56 AEOL # 56 EOquin 56 Aerovance 56 HDACi 56 Genitope Corporation 56 Intellikine 56 sodium thiosulfate STS 56 thorough QTc 56 Sopherion 56 Phase 1b clinical trials 56 ridaforolimus 56 OMNARIS HFA 56 MLN# 56 Phase IIIb 56 Vicriviroc 56 multi kinase inhibitor 56 brentuximab vedotin SGN 56 CMV vaccine 56 2 methoxyestradiol 56 Asentar 56 CHDI Foundation 56 ATryn R 56 dextromethorphan quinidine 56 vilazodone 56 SILENOR 56 Pafuramidine 56 Phase IIb Trial 56 DAVANAT ® 56 FavId 56 anti botulism antibody 56 PsychoGenics 56 fostamatinib 56 LGLS 56 carcinogenicity study 56 ANAVEX 56 TELCYTA 56 systemically administered 56 Ophena TM 56 Soliris TM eculizumab 56 EV# vaccine 56 BiTE antibody 56 HIV integrase inhibitors 56 prokinetic agent 56 LymphoStat B TM 56 Tyrima 56 HEPLISAV ™ 56 Thorough QT 56 RhuDex 56 APF# 56 fipamezole 56 Galenea 56 GSK # 56 Shigamabs 56 Application BLA 56 Aflibercept 56 torezolid 56 iSONEP 56 ONX 56 MCSP respectively 56 Urokinase 56 Tezampanel 56 Capesaris 56 Phase #/#a trial 56 Immunotherapeutic 56 Ceflatonin 56 orally administered 56 Marqibo 56 Actilon 56 NitroMist TM 56 XmAb 56 Plenaxis TM 56 PEGPH# 56 generation HCV protease 56 Restanza 56 dasatinib Sprycel ® 56 rhThrombin 56 Relovair 56 zolpidem tartrate sublingual tablet 56 ARRY # 56 Initiates Phase II 56 single ascending dose 56 Lovaxin C 56 RH1 56 CYT# potent vascular disrupting 56 Celgosivir 56 AZX# 56 Unit Dose Budesonide 56 exploratory Phase IIa 56 Litx 55 gemcitabine Gemzar ® 55 tremelimumab 55 novel L DOS# 55 Sphingomab TM 55 postapproval 55 immunotherapeutic vaccine 55 PDE# inhibitors 55 therapeutic peptide 55 adrenergic regulation 55 Phase III registrational 55 HuMax CD4 55 delivers fluocinolone acetonide FA 55 Lenocta TM 55 BLP# Liposome Vaccine 55 investigational monoclonal antibody 55 tasimelteon 55 faropenem medoxomil 55 Micromet BiTE 55 Zingo TM 55 thrombin inhibiting aptamer 55 injectable formulation 55 Homspera 55 Voraxaze 55 RAV# 55 bioequivalency 55 LOMUCIN TM 55 miconazole Lauriad ® 55 PRECISE trial 55 prostone 55 rhC1INH 55 investigational pan BCR 55 selective immunoproteasome inhibitor 55 Pharmos proprietary 55 Clevudine 55 Cethromycin 55 atacicept 55 GRN#L 55 BioNumerik 55 Ceplene TM 55 BRILINTA 55 sodium Injection 55 Pancreate 55 generation antisense 55 Lisofylline LSF 55 nanoviricides 55 pharmacokinetic PK study 55 EpiCept NP 1 55 NOXXON 55 Enzyme Replacement Therapy 55 AVE# 55 Phase #/#a clinical 55 sapacitabine 55 SparVax ™ 55 cMET 55 Sapacitabine 55 Scil Proteins 55 Chemokine Therapeutics 55 nanopharmaceutical 55 RNAi therapeutic targeting 55 Ketotransdel 55 bremelanotide 55 Lu AA# 55 candidate ATHX 55 product candidate Lpathomab 55 denosumab oncology 55 initiate multicenter 55 systemic RNAi 55 Xcytrin R 55 investigational antiplatelet agent 55 oral picoplatin 55 IND Filing 55 DDP# 55 Cempra 55 Cenomed 55 CRACM 55 albinterferon alfa 2b 55 renin inhibitors 55 SNS# T 55 Locteron ® 55 StemEx 55 budiodarone 55 resolvin 55 Lixivaptan 55 TOPIGEN 55 pharmacogenomic translational research 55 ALTU 55 XL# [003] 55 REMOXY R 55 Successfully Completes Phase 55 Junovan TM 55 diarrhea predominant irritable 55 ONCONASE 55 pharmacokinetic studies 55 EnzymeRx 55 ESBA# 55 transmucosal delivery system 55 novel therapeutic antibodies 55 Ozarelix 55 belinostat 55 dose cohort 55 unpartnered 55 UVIDEM 55 Proxinium TM 55 BCR ABL inhibitor 55 palifosfamide 55 mipomersen 55 novel oral anticoagulant 55 Solzira 55 Biologics License Application 55 Expression Genetics 55 MDS AML 55 IMC A# 55 radiotherapeutic 55 BioSante LibiGel Phase III 55 EVIZON TM 55 BNC# 55 Ecallantide 55 novel VDA molecule 55 HSP# inhibitor 55 Soliris eculizumab 55 DiObex 55 Squalamine 55 YONDELIS 55 Evamist TM 55 HuMax CD# 55 Maxy G# 55 BIM #A# 55 OMAPRO 55 Panzem ® 55 JAK3 inhibitor 55 GATTEX ® 55 human IgG1 monoclonal 55 hormone LHRH antagonist 55 solithromycin 55 IIb clinical trial 55 GAMMAGARD 55 rALLy trial 55 Vascular Disrupting Agent 55 Pivotal Phase 55 carfilzomib 55 ruxolitinib 55 fosbretabulin 55 TOCOSOL Camptothecin 55 Azedra 55 biased ligand 55 VITAL Trial 55 NEUGENE antisense 55 generation calcineurin inhibitor 55 optimal dosing regimens 55 vivo efficacy 55 recombinant subunit vaccine 55 MEND CABG 55 anticoagulant reversing agent 55 Hedgehog Pathway Inhibitor 55 placebo controlled Phase 55 ALN HTT 55 Alocrest 55 Neo Urinary Conduit 55 Xanafide 55 Generx TM 55 ISENTRESS raltegravir 55 candidates bavituximab 55 proteasome inhibitor 55 Tarsa Therapeutics 55 Addrenex 55 GATTEX ™ 55 Gemin X 55 naronapride 55 non alcoholic steatohepatitis 55 ImQuest 55 Luramist 55 Dextofisopam 55 AQUAVAN R 55 MNTX 55 Altropane